- Home
- ACRS vs LAKE Comparison
ACRS vs LAKE Comparison
Compare ACRS & LAKE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- LAKE
- Stock Information
- Founded
- ACRS 2012
- LAKE 1982
- Country
- ACRS United States
- LAKE United States
- Employees
- ACRS N/A
- LAKE N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- LAKE Industrial Specialties
- Sector
- ACRS Health Care
- LAKE Health Care
- Exchange
- ACRS Nasdaq
- LAKE Nasdaq
- Market Cap
- ACRS 198.2M
- LAKE 161.5M
- IPO Year
- ACRS 2015
- LAKE 1986
- Fundamental
- Price
- ACRS $2.26
- LAKE $16.69
- Analyst Decision
- ACRS Strong Buy
- LAKE Strong Buy
- Analyst Count
- ACRS 9
- LAKE 3
- Target Price
- ACRS $9.25
- LAKE $25.00
- AVG Volume (30 Days)
- ACRS 1.5M
- LAKE 133.6K
- Earning Date
- ACRS 11-06-2025
- LAKE 12-04-2025
- Dividend Yield
- ACRS N/A
- LAKE 0.72%
- EPS Growth
- ACRS N/A
- LAKE N/A
- EPS
- ACRS N/A
- LAKE N/A
- Revenue
- ACRS $16,789,000.00
- LAKE $191,631,000.00
- Revenue This Year
- ACRS N/A
- LAKE $29.73
- Revenue Next Year
- ACRS N/A
- LAKE $8.45
- P/E Ratio
- ACRS N/A
- LAKE N/A
- Revenue Growth
- ACRS N/A
- LAKE 39.13
- 52 Week Low
- ACRS $1.05
- LAKE $12.76
- 52 Week High
- ACRS $5.17
- LAKE $27.28
- Technical
- Relative Strength Index (RSI)
- ACRS 53.36
- LAKE 56.62
- Support Level
- ACRS $2.24
- LAKE $15.90
- Resistance Level
- ACRS $2.70
- LAKE $17.72
- Average True Range (ATR)
- ACRS 0.23
- LAKE 0.62
- MACD
- ACRS 0.01
- LAKE -0.05
- Stochastic Oscillator
- ACRS 46.34
- LAKE 43.43
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
About LAKE Lakeland Industries Inc.
Lakeland Industries Inc manufactures and sells safety garments and accessories for the industrial protective clothing market. Its product segments include Disposables, Chemicals, Fire, Gloves, High Visibility, High-Performance Wear, and Wovens. Its customers include integrated oil, chemical/petrochemical, utilities, automobile, steel, glass, construction, smelting, munition plants, janitorial, pharmaceutical, and mortuaries, as well as scientific and medical laboratories. Its geographical segments include the United States, Latin America, Canada, Asia, Mexico, Europe (United Kingdom), and Other Foreign.